All In Biotech

Drug Trial Radar · NCT07511556

First-in-human Study of UX016 in GNEM

A Phase 1/2, First-in-human, Double-blind, Placebo-controlled Study to Assess Dose, Safety, and Efficacy of UX016 (Sialic Acid-C16 Prodrug) in Adults With GNE Myopathy

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety and dose of UX016 and its impact on muscle strength in adults with GNE Myopathy (GNEM).

Conditions

  • GNE Myopathy

Interventions

  • UX016Drug

    Tablets for oral use

  • PlaceboOther

    Tablets for oral use. Tablets will match the UX016 tablets, but contain no active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 96 (Double Blind and Extension Periods)
  2. Upper Extremity Composite (UEC) Score Change From BaselineTime frame: Baseline, 48 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Orange, California · Recruiting

  • Rare Disease Research

    Iselin, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.